Cadila Healthcare tumbles on getting warning letter from US FDA

31 Dec 2015 Evaluate

Cadila Healthcare is currently trading at Rs. 334.35, down by 50.80 points or 13.19% from its previous closing of Rs. 385.15 on the BSE.

The scrip opened at Rs. 385.15 and has touched a high and low of Rs. 385.40 and Rs. 327.40 respectively. So far 450731 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 454.40 on 23-Oct-2015 and a 52 week low of Rs. 285.02 on 05-Feb-2015.

Last one week high and low of the scrip stood at Rs. 394.95 and Rs. 327.40 respectively. The current market cap of the company is Rs. 38702.59 crore.

The promoters holding in the company stood at 74.79 % while Institutions and Non-Institutions held 15.08 % and 10.13 % respectively.

Cadila Healthcare has received a Warning Letter issued by the US FDA relating to its Moraiya formulation facility and Ahmedabad API facility (Zyfine). The company will respond to US FDA to address the observations within the statutory time permitted in the letter. The company is committed to resolve all the issues and revamp its quality systems and processes as the top most priority.

Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. It is the only Indian pharma company to launch its own patented NCE - Lipaglyn, the world’s first drug to be approved for the treatment of diabetic dyslipidemia.

 

Zydus Lifesciences Share Price

931.45 -3.75 (-0.40%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×